Company Monitoring Page for Sandoz

latest headlines for company on cafepharma

Amgen cannot stop imminent sale of Neupogen copycat: US appeals court
Yahoo/Reuters
Wed, 09/2/15 - 12:37 pm
Tags:
Amgen, Neupogen, biosimilars, Zarxio, Novartis, Sandoz
Amgen: Waiting for Clarity on Generic Biotech
Barron's
Fri, 08/21/15 - 11:05 am
Tags:
Amgen, generics, biosimilars, Novartis, Sandoz, Neupogen, Zarxio
AbbVie And Amgen Threatened By Biosimilars
Bidness, ETC
Mon, 08/17/15 - 07:57 am
Tags:
AbbVie, Amgen, biosimilars, JNJ, Sandoz, Novartis, Humira, Neupogen, Remicade, Nuelasta, Enbrel, epoetin-alfa
Why Sandoz Revenues Were Important for Novartis in 2Q15
Yahoo/Market Realist
Wed, 07/29/15 - 12:43 pm
Tags:
Novartis, Sandoz, generics, earnings
Sandoz closing three German and Indian factories
BioPharma Dive
Tue, 07/28/15 - 10:14 am
Tags:
Sandoz, Novartis, generics, Germany, India
Novartis whacks 3 Sandoz plants, 770 jobs, despite generic units' sales growth
Fierce Pharma
Thu, 07/23/15 - 11:30 pm
Tags:
Novartis, Sandoz, generics, drug manufacturing
Novartis blocked from selling Neupogen copycat until Sept. 2
Yahoo/Reuters
Tue, 07/21/15 - 12:47 pm
Tags:
Novartis, biosimilars, Neupogen, Zarxio, Sandoz, Amgen
Novartis off to scorching start with Copaxone generic Glatopa
Fierce Pharma Marketing
Mon, 07/13/15 - 11:11 am
Tags:
Novartis, Copaxone, generics, Glatopa, MS, multiple scleroiss, Momenta, Sandoz
It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA
Fierce Pharma Marketing
Mon, 06/22/15 - 10:52 am
Tags:
Teva Pharmaceutical, Momenta, Sandoz, generics, Novartis, Copaxone, MS, multiple sclerosis
U.S. court nixes Teva's Copaxone patent--again
Fierce Pharma
Thu, 06/18/15 - 04:00 pm
Tags:
Copaxone, patents, Teva Pharmaceuticals, generics, Momenta, Novartis, Sandoz
Novartis tries to get U.S. ban lifted on sale of Neupogen copycat
Yahoo/Reuters
Wed, 06/3/15 - 07:37 pm
Tags:
Novartis, Neupogen, biosimilars, Zarxio, Amgen, Sandoz
Amgen motion to delay Neupogen biosimilar denied
Medical Marketing and Media
Fri, 04/17/15 - 08:44 am
Tags:
Amgen, Neupogen, biosimilars, Zarxio, Novartis, Sandoz
Denied Again! Another Obstacle to Biosimilar First Launch Falls with FDA Rejection of Amgen’s Certification Petition
FDA Law Blog
Fri, 03/27/15 - 08:39 am
Tags:
Amgen, biosimilars, FDA, Sandoz, Neupogen, Zarxio
U.S. judge rejects Amgen injunction bid against Novartis Sandoz unit
Yahoo/Reuters
Fri, 03/20/15 - 11:00 am
Tags:
Amgen, Neupogen, Novartis, Sandoz, biosimilars
Novartis Pays $12.6M Fine for Giving Inaccurate Pricing Data to Medicare
WSJ Pharmalot
Mon, 03/16/15 - 03:00 pm
Tags:
Novartis, Sandoz, Medicare
Novartis wins approval for first U.S. biosimilar drug
Yahoo/Reuters
Fri, 03/6/15 - 10:01 am
Tags:
Novartis, FDA, Neupogen, Zarxio, Sandoz, Amgen
Sandoz gets ready to make the biosimilar case with oncologists
Medical Marketing and Media
Thu, 01/22/15 - 09:51 am
Tags:
Sandoz, biosimilars, physicians, oncologists, Neupogen, Zarxio, Novartis
Drug companies find common ground over Colorado's 'biosimilars' legislation
Bizjournals.com
Wed, 01/21/15 - 09:42 am
Tags:
Colorado, biologics, generics, Amgen, Sandoz
FDA panel recommends approval for first generic biotech drug
Marketwatch
Wed, 01/7/15 - 06:49 pm
Tags:
FDA, advisory panels, biosimilars, Neupogen, Amgen, Novartis, Sandoz
Novartis copy of Amgen biotech drug shows similar efficacy-study
Yahoo/Reuters
Mon, 12/8/14 - 08:24 am
Tags:
Novartis, Amgen, Neupogen, biosimilars, Sandoz, neutropenia

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.